US 8,298,536

Application 12/920,634 · Granted Oct 30, 2012

Methods of treating inflammatory pain

Estimated expiration

March 3, 2029

2y 102d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTIB2009050849: Resource not found (404)
Earliest effective filing
Mar 3, 2009
+ 20 years
Mar 3, 2029
PTA +0d
Mar 3, 2029
No TD
—
Final
Mar 3, 2029

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
September 2, 2010
Earliest effective filing
March 3, 2009
Issue date
October 30, 2012
PTA
0 days
Base expiry (before PTA)
March 3, 2029

March 3, 2009 + 20 years = March 3, 2029

  • National stage entry of application PCTIB2009050849, filed Mar 3, 2009
  • PRO61/033,568 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 12/920,634 · US 8,298,536

PatentReply compiles the prosecution history behind US 8,298,536: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US8298536

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.